

Synthesis of 4-Isoxazolines through Gold(I)-Catalyzed Cyclization of Propargylic N-Hydroxylamines

Bandari Chandrasekhar, Sewon Ahn, and Jae-Sang Ryu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b01499 • Publication Date (Web): 15 Jul 2016

Downloaded from <http://pubs.acs.org> on July 17, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Synthesis of 4-Isoxazolines through Gold(I)-Catalyzed Cyclization of Propargylic *N*-Hydroxylamines

B. Chandrasekhar, Sewon Ahn and Jae-Sang Ryu*

College of Pharmacy & Graduate School of Pharmaceutical Sciences, Ewha Womans University, 52
Ewhayeodae-gil, Seodaemun-Gu, Seoul 03760, Republic of Korea.

AUTHOR EMAIL ADDRESS: ryuj@ewha.ac.kr

CORRESPONDING AUTHOR FOOTNOTE: Fax+82 2 3277 2851; Tel: +82 2 3277 3008



ABSTRACT: New catalytic methods for the synthesis of 4-isoxazolines have been developed via catalytic intramolecular cyclizations of propargylic *N*-hydroxylamines. The reactions proceed rapidly in less than one hour at room temperature in the presence of 5 mol% (PPh₃)AuCl/5 mol% AgOTf or 5 mol% (PPh₃)AuNTf₂. This process features an efficient route to 4-isoxazolines with high yields, short reaction times, and mild reaction conditions.

Introduction

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4-Isoxazolines¹ (2,3-dihydroisoxazoles) are not only important scaffolds for various biologically active compounds,² but are also versatile synthetic intermediates for the preparation of interesting natural products.³ The reductive opening of 4-isoxazolines provides access to building blocks such as β -amino ketones,⁴ β -amino alcohols,⁴ and β -lactams.⁵ In addition, due to the thermal instability of the N-O bond associated with the π -system, 4-isoxazolines can be thermally or catalytically isomerized to various structures such as 2-acylaziridine,⁶ 4-oxazoline,⁷ and pyrrole⁸ (Figure 1). Although their value in both chemistry and biology has been widely recognized, only a few methods to obtain such scaffolds have been described so far: the [3+2] cycloadditions between nitrones and alkynes,⁹ cycloadditions between oxaziridines and alkynes,¹⁰ and the cyclization of propargylic *N*-hydroxylamines. Among these, the 1,3-dipolar cycloaddition of nitrones to acetylenes is one of the most attractive approaches to the synthesis of 4-isoxazolines. However, this method often suffers from poor regioselectivity and limited substrate scope for alkynes (e.g., acetylene carboxylates and related electron-deficient acetylenes). Recently, the cyclization of propargylic *N*-hydroxylamines has emerged as an alternative pathway for the synthesis of 4-isoxazolines, and not surprisingly, only a few catalytic methods have been reported to date. Such a transformation can be accelerated by Pd(OAc)₂,¹¹ ZnI₂-DMAP,¹² NaAuCl₄•2H₂O-DMAP,¹³ AgBF₄,¹⁴ or ZnMe₂.¹⁵ Although these methods provide synthetic routes to 4-isoxazolines with the desired regioselectivity, some of these methods require additional bases (Et₃N or DMAP), rather long reaction times (12–48 h for Pd(OAc)₂), high temperatures, or high loading of catalysts (10–300 mol%). Therefore, the development of mild and efficient catalytic conditions to facilitate access to synthetically useful 4-isoxazolines is still needed. In the course of our studies on gold-catalyzed reactions to construct complex heterocycles, we developed a highly efficient synthetic method, which can produce 4-isoxazolines in very short times. Herein, we report a mild gold(I)-catalyzed cyclization of propargylic *N*-hydroxylamines to yield 4-isoxazolines at room temperature in 5–60 minutes.





Figure 1. 4-Isioxazoline as a versatile synthetic intermediate.

Results and Discussion

Although gold(III) catalyzes the cyclization of propargylic *N*-hydroxylamines in the presence of 20 mol% of DMAP under refluxing CH_2Cl_2 conditions, gold(I)-catalyzed cyclization has long been elusive.¹³ To assess the feasibility of gold(I)-catalyzed cyclization of propargylic *N*-hydroxylamine, we began to investigate the cycloisomerization of *N*-benzyl-*N*-(1,3-diphenylprop-2-yn-1-yl)hydroxylamine (**1a**) in the presence of various gold(I) and gold(III) catalysts in CH_2Cl_2 at room temperature (Table 1). First, we carried out cyclization reactions using cationic phosphine Au(I) chloride catalysts. $(\text{PPh}_3)\text{AuCl}$ produced the cyclization product **2a** in 33% yield after 48 h but 66% starting material was recovered (Table 1, entry 1). Unfortunately, this reaction was sluggish and other phosphine ligands such as PCy_3 and PMe_3 could not improve the result (entries 2 and 3). An NHC ligand such as IPr was not effective, either (entry 4). As expected, gold(III) catalysts such as AuCl_3 or $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O}$ facilitated the reaction and afforded the cyclized product **2a** in 56% and 51% yields, respectively (entries 5 and 6). However, these catalysts also produced the undesired byproduct chalcone (**3a**), which was presumably generated from the addition of gold(III) catalyst to the already formed 4-isioxazoline **2a** during the reaction and the subsequent hydrolysis of **I-3** during workup (Scheme 1). Molecular sieve removal of H_2O and flash chromatography could not prevent the formation of **3a**. This might originate from the intrinsic properties of gold(III) catalysts to easily form a complex with 4-isoxazolines.¹³ Indeed, the reaction of **2a** and AuCl_3 afforded **3a** in 30% yield with complicated unidentified byproducts after 48 h (eq 1). To our surprise, the gold(I) catalyst, AuCl afforded **2a** as a sole product in 15 min (entry 7). The reaction

was very rapid and no byproduct formation was observed. After a series of optimization studies, (PPh₃)AuNTf₂ (5 mol%) was identified as the best catalyst for the cyclization reaction (entry 8). In the presence of (PPh₃)AuNTf₂ (5 mol%), 4-isoxazoline **2a** was isolated in 91% yield after 15 min at room temperature without the formation of **3a**.


Table 1. Catalyst Screening and Optimization of Reaction Conditions.^a




entry	Au-catalyst	time (h)	yield (%) ^b		
			2a	3a	Rec 1a ^c
1	(PPh ₃)AuCl	48	33	0	66
2	(PCy ₃)AuCl	48	14	0	85
3	(PMe ₃)AuCl	48	14	0	85
4	(IPr)AuCl	48	26	0	72
5	AuCl ₃	0.1	56	24	0
6	NaAuCl ₄ ·2H ₂ O	0.2	51	29	0
7	AuCl	0.25	83	0	0
8	(PPh ₃)AuNTf ₂	0.25	91	0	0

^a Reaction conditions: **1a** (62.6 mg, 200 μmol), Au-catalyst (10.0 μmol, 5 mol%), CH₂Cl₂ (2 mL). ^b Isolated yields after flash column chromatography. ^c Recovered **1a**.


Scheme 1. Plausible Mechanism for the Formation of **3a**.





The significant difference in the reactivity of $(\text{PPh}_3)\text{AuCl}$ and $(\text{PPh}_3)\text{AuNTf}_2$ prompted us to further investigate the effect of anion and silver co-catalysts on the cyclization reaction as shown in Table 2. Interestingly, the addition of 5 mol% of silver salts to the $(\text{PPh}_3)\text{AuCl}$ reaction remarkably accelerated the cyclization process. The reactions were completed in 0.5–1 hours and afforded **2a** as the sole product in 79–90% yield (Table 2, entries 1–6). Particularly, the reaction using $(\text{PPh}_3)\text{AuCl}/\text{AgNTf}_2$ gave **2a** with a comparable yield to the reaction using $(\text{PPh}_3)\text{AuNTf}_2$ (1 h, 87%, Table 2, entry 4, vs 0.25 h, 91%, Table 1, entry 8). The best result was obtained with $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$, which afforded the 4-isoxazoline **2a** in 90% in 0.5 h. Meanwhile, the AuCl/AgOTf reaction was slower than the $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$ reaction and 3% of byproduct chalcone (**3a**) was isolated (Table 2, entry 7).

According to the previous literature,¹⁴ AgBF_4 is known to catalyze the cyclization. However, AgOTf was not an effective catalyst. When it was employed alone, only 24% of **2a** was obtained after 48 h along with 54% of byproduct **3a** (Table 2, entry 8). Obviously, the $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$ system exhibited better activity than $(\text{PPh}_3)\text{AuCl}$ or AgOTf alone, which might be because of the silver salt effect¹⁶ or anion effect. Therefore, in order to compare the silver salt effect and the anion effect, we carried out the cyclization reaction in the presence of $(\text{PPh}_3)\text{AuOTf}$ prepared by premixing $(\text{PPh}_3)\text{AuCH}_3$ and TfOH in the absence of silver salts, which provided 4-isoxazoline **2a** in 76% yield and **3a** in 5% yield respectively after 5 min (Table 2, entry 9). The reaction was rapid and comparably efficient. Therefore, the anion effect was evidently significant. Although AgOTf alone can catalyze the cyclization, the remarkable reactivity of the $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$ system must originate from the intrinsic activity of Au(I)-catalyst and its anion. As another evidence of this, $(\text{PPh}_3)\text{AuNTf}_2$ alone without any silver salt catalyzed the cyclization of propargylic *N*-hydroxylamines with comparable reactivity (*vide supra*). Interestingly, TfOH alone could not catalyze the cyclization and was unable to generate **2a** and **3a** (Table 2, entry 10).

Table 2. The Silver Salt and Solvent Effect on the Cyclization.^a

entry	catalyst	solvent	time (h)	yield (%) ^b	
				2a	3a
1	(PPh ₃)AuCl/AgOTs	CH ₂ Cl ₂	0.5	82	0
2	(PPh ₃)AuCl/AgSbF ₆	CH ₂ Cl ₂	0.5	79	0
3	(PPh ₃)AuCl/AgBF ₄	CH ₂ Cl ₂	0.75	82	0
4	(PPh ₃)AuCl/AgNTf ₂	CH ₂ Cl ₂	1	87	0
5	(PPh ₃)AuCl/AgNO ₃	CH ₂ Cl ₂	1	79	0
6	(PPh ₃)AuCl/AgOTf	CH ₂ Cl ₂	0.5	90	0
7	AuCl/AgOTf	CH ₂ Cl ₂	4	76	3
8	AgOTf	CH ₂ Cl ₂	48	24	54
9 ^c	(PPh ₃)AuCH ₃ /TfOH	CH ₂ Cl ₂	0.1	76	5
10	TfOH	CH ₂ Cl ₂	48	NR ^d	-
11	(PPh ₃)AuCl/AgOTf	THF	0.5	90	0
12	(PPh ₃)AuCl/AgOTf	CH ₃ CN	1.5	90	0
13	(PPh ₃)AuCl/AgOTf	Toluene	0.25	94	0
14 ^c	(PPh ₃)AuNTf ₂	Toluene	0.5	90	0


^a Reaction conditions: **1a** (62.6 mg, 200 μmol), Au-catalyst (10.0 μmol, 5 mol%), Ag-salt (10.0 μmol, 5 mol%), CH₂Cl₂ (2 mL). ^b Isolated yields after flash column chromatography. ^c TfOH (10.0 μmol, 5 mol%) was used instead of Ag-salt. ^d No reaction.

Au(I)-catalyzed cyclization reactions of propargylic *N*-hydroxylamines showed a negligible solvent effect on the yield and the reaction time. The reactions were effective in various solvents such as CH₂Cl₂, THF, CH₃CN, and toluene (Table 2, entry 6 and entries 11–14). Based on table 2, we chosen the relatively non-polar solvent, toluene for further study (Table 2, entries 13 and 14).

After we identified (PPh₃)AuCl/AgOTf and (PPh₃)AuNTf₂ as the best catalysts, we investigated the scope of Au(I)-catalyzed cyclization reactions of propargylic *N*-hydroxylamines using


(PPh₃)AuCl/AgOTf or (PPh₃)AuNTf₂ independently under optimized conditions (Scheme 2). Both the (PPh₃)AuCl/AgOTf catalyst system and the (PPh₃)AuNTf₂ catalyst worked well with a wide variety of substrates and showed broad functional group compatibility. The cyclization yields are fully comparable and independent of the electronic nature. Substrates **1b–d** bearing electron-donating substituents as R³ group underwent the cyclization reactions very smoothly and provided the corresponding 4-isoxazolines **2b–d** at room temperature in good to excellent yields (76–99%). Substrates **1e–i** bearing electron-withdrawing substituents as R³ groups also provided the desired 4-isoxazolines **2e–i** in good yields (68–98%) under the same reaction conditions. Evidently, no reactivity difference between the (PPh₃)AuCl/AgOTf catalyst system and the (PPh₃)AuNTf₂ was observed. The Au(I)-catalyzed cyclization reaction was also applicable to the substrates carrying aliphatic, naphthyl, thiophenyl substituents as R³ to deliver the corresponding 4-isoxazolines (**2j–l** and **2r**). Modifications to the R¹ and R² groups were carried out as well. The substrates bearing electron-donating *p*-methoxyphenyl, electron-withdrawing *p*-nitrophenyl and aliphatic groups in the R² underwent clean conversion to 4-isoxazolines (**2m–o**, **2r**, and **2s**). The benzyl group in R¹ could be replaced with a *p*-methoxybenzyl (PMB) group and a *t*-butyl group without loss of reactivity. Although bulky *t*-butyl substituted 4-isoxazoline **2q** was very unstable and decomposed to **3a** during column chromatography, **2q** was successfully isolated in over 90% yield by rapid flash chromatography.

Scheme 2. Synthesis of 4-Isoxazolines under Optimized Conditions.




Condition A: (PPh₃)AuCl (5 mol%)/AgOTf (5 mol%)

Condition B: (PPh₃)AuNTf₂ (5 mol%)



44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Moreover, the potential of this reaction was further proved by preliminary experiments using optically active propargylic *N*-hydroxylamine (eq 2). The enantioenriched propargylic *N*-hydroxylamine, (*R*)-**1a** can be cyclized without loss in enantiopurity, which suggests that this reaction is mild enough to allow 4-isoxazolines from enantiopure propargylic *N*-hydroxylamines under preservation of the stereochemical integrity. Therefore, it is applicable to the stereoselective synthesis of 4-isoxazolines when it is coupled to diastereoselective or enantioselective synthesis of propargylic *N*-hydroxylamine.



27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Mechanistically, we speculate that Au(I) catalyst **A** coordinates with the alkyne of **1a** and subsequent cyclization leads to the Au(I) complex **C**. Subsequent deprotonation generates the Au(I) complex **D**, which readily decomposes to yield protodeaurated 4-isoxazoline **2a** and regenerates the cationic gold(I) catalyst **A** (Scheme 3).

Scheme 3. Plausible Mechanism.



Conclusions

48
49
50
51
52
53
54
55
56
57
58
59
60

In conclusion, we have successfully developed an efficient gold-catalyzed cyclization of propargylic *N*-hydroxylamines to furnish synthetically valuable 4-isoxazolines under mild conditions (room temperature, 5 mol% catalyst loading) in short reaction times (5–60 minutes). This is the first report on the construction of 4-isoxazolines using gold(I)-catalyzed intramolecular cyclization. We believe that

1 this methodology will be very useful in synthetic organic chemistry and medicinal chemistry. Its
2 application to the synthesis of bioactive natural products is currently underway in our laboratory.
3
4
5
6

7 **Experimental Section**

9
10 **General Methods** All reactions were performed in oven-dried glassware fitted with a glass stopper
11 under positive pressure of Ar with magnetic stirring, unless otherwise noted. Air- and moisture-sensitive
12 liquids and solutions were transferred via syringe or stainless-steel cannula. TLC was performed on 0.25
13 mm E. Merck silica gel 60 F₂₅₄ plates and visualized under UV light (254 nm) or by staining with
14 cerium ammonium molybdenate (CAM), potassium permanganate (KMnO₄) or *p*-anisaldehyde. Flash
15 chromatography was performed on E. Merck 230–400 mesh silica gel 60. Reagents were purchased
16 from commercial suppliers, and used without further purification unless otherwise noted. Solvents were
17 distilled from proper drying agents (CaH₂ or Na wire) under Ar atmosphere at 760 mm Hg. All
18 moisture- and/or oxygen-sensitive solids were handled and stored in a glove box under N₂. NMR spectra
19 were recorded at 24 °C. Chemical shifts are expressed in ppm relative to TMS (¹H, 0 ppm), CDCl₃ (¹H,
20 7.26 ppm; ¹³C, 77.2 ppm), C₆D₆ (¹H, 7.16 ppm; ¹³C, 128.1 ppm), acetone-*d*₆ (¹H, 2.05 ppm; ¹³C, 206.2,
21 29.9 ppm), and C₆H₅F (¹⁹F, –113.15 ppm); coupling constants are expressed in Hz. High resolution
22 mass spectra (HRMS) were obtained by electrospray ionization (ESI) or electron ionization (EI).
23 Infrared spectra were recorded with peaks reported in cm⁻¹.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Procedure for the synthesis of nitrone S1a–f.**

46
47 (*Z*)-*N*-Benzylidene-benzylamine-*N*-oxide (**S1a**).¹⁷ *N*-Benzylhydroxylamine (2.00 g, 16.2 mmol, 1.00
48 equiv), benzaldehyde (1.65 mL, 16.2 mmol, 1.00 equiv) and anhydrous MgSO₄ (1.95 g, 16.2 mmol, 1.00
49 equiv) were suspended in anhydrous CH₂Cl₂ (80 mL). After stirring at room temperature for 15 h, the
50 resulting suspension was filtered and washed with CH₂Cl₂ (100 mL). The filtrate was concentrated by
51 rotary evaporation. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford
52 (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (3.40 g, 99%) as a white solid. TLC: *R*_f 0.45 (1:1
53
54
55
56
57
58
59
60

1 hexane/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 8.22–8.19 (m, 2H), 7.49–7.39 (m, 9H), 5.06 (s, 2H).

2 ^{13}C NMR (100 MHz, CDCl_3): 134.6, 133.3, 130.6, 130.5, 130.0, 129.3, 129.0, 128.8, 128.5, 71.3.

3
4
5 HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{13}\text{NNaO}$ [$\text{M} + \text{Na}$] $^+$ 234.0889, found 234.0896.

6
7
8 *(Z)*-*N*-(4-Methoxybenzylidene)-1-phenylmethanamine oxide (**S1b**).¹⁸ *N*-Benzylhydroxylamine (493
9 mg, 4.00 mmol, 1.00 equiv), *p*-methoxybenzaldehyde (535 μL , 4.40 mmol, 1.10 equiv) and 4 Å
10 molecular sieves (500 mg) were suspended in anhydrous toluene (12 mL). After stirring at room
11 temperature for 12 h, the resulting suspension was filtered and washed with CH_2Cl_2 (20 mL). The
12 filtrate was concentrated by rotary evaporation. Recrystallization from hexanes/EtOAc (4:1) afforded
13 **S1b** (960 mg, 99%) as a white solid. TLC: R_f 0.35 (1:1 hexane/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ
14 8.20 (d, $J = 8.8$ Hz, 2H), 7.46 (dd, $J = 8.0$ Hz, 2.0 Hz, 2H), 7.42–7.36 (m, 3H), 7.32 (s, 1H), 6.90 (d, $J =$
15 8.8 Hz, 2H), 5.01 (s, 2H), 3.84 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): 161.3, 134.2, 133.6, 130.8, 129.3,
16 129.1, 129.0, 123.5, 113.9, 70.8, 55.5. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{15}\text{NNaO}_2$ [$\text{M} + \text{Na}$] $^+$ 264.0995,
17 found 264.1001.

18
19
20
21
22
23
24
25
26
27
28
29
30
31 *(Z)*-*N*-(4-Nitrobenzylidene)-1-phenylmethanamine oxide (**S1c**).¹⁸ *N*-Benzylhydroxylamine (493 mg,
32 4.00 mmol, 1.00 equiv), *p*-nitrobenzaldehyde (664 mg, 4.40 mmol, 1.10 equiv) and 4 Å molecular
33 sieves (500 mg) were suspended in anhydrous toluene (12 mL). After stirring at room temperature for
34 12 h, the resulting suspension was filtered and washed with CH_2Cl_2 (20 mL). The filtrate was
35 concentrated by rotary evaporation. The residue was purified by column chromatography (1:1
36 hexane/EtOAc) to afford **S1c** (830 mg, 81 %) as a yellow solid. TLC: R_f 0.55 (1:1 hexane/EtOAc). ^1H
37 NMR (400 MHz, CDCl_3): δ 8.36 (d, $J = 9.2$ Hz, 2H), 8.23 (d, $J = 9.2$ Hz, 2H), 7.52 (s, 1H), 7.50–7.48
38 (m, 2H), 7.45–7.43 (m, 3H), 5.11 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3): 148.0, 136.2, 132.7, 132.3,
39 129.6, 129.5, 129.3, 129.0, 123.9, 72.2. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$ 257.0921,
40 found 257.0925.

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 *(Z)*-*N*-(2-Methylpropylidene)benzylamine-*N*-oxide (**S1d**).¹⁷ *N*-Benzylhydroxylamine (247 mg, 2.00
56 mmol, 1.00 equiv), 2-methylpropionaldehyde (183 μL , 2.00 mmol, 1.00 equiv) and anhydrous MgSO_4
57 (240 mg, 2.00 mmol, 1.00 equiv) were suspended in anhydrous Et_2O (10 mL). After Stirring at room
58
59
60

1 temperature for 15 h, the resulting suspension was filtered and washed with CH₂Cl₂ (20 mL). The
2 filtrate was concentrated by rotary evaporation. Recrystallization from hexanes/EtOAc (4:1) afforded
3 **S1b** (230 mg, 65%) as a white solid. TLC: *R_f* 0.15 (3:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ
4 7.4–7.35 (m, 5H), 6.47 (d, *J* = 7.2 Hz, 1H), 4.86 (s, 2H), 3.16 (sept, *J* = 6.4 Hz, 1H), 1.08 (d, *J* = 6.4 Hz,
5 6H). ¹³C NMR (100 MHz, CDCl₃): 144.7, 133.2, 129.2, 129.0, 128.9, 69.4, 26.1, 18.9. HRMS (ESI) *m/z*
6 calcd for C₁₁H₁₅NNaO [M+ Na]⁺ 200.1046, found 200.1055.

7
8
9
10
11
12
13
14 *(Z)*-*N*-Benzylidene-1-(4-methoxyphenyl)methanamine oxide (**S1e**).¹⁹ *N*-(4-
15 Methoxybenzyl)hydroxylamine (766 mg, 5.00 mmol, 1.00 equiv), benzaldehyde (508 μL, 5.00 mmol,
16 1.00 equiv) and anhydrous MgSO₄ (600 mg, 5.00 mmol, 1.00 equiv) were suspended in anhydrous
17 CH₂Cl₂ (25 mL). After stirring for 12 h at room temperature, the resulting suspension was filtered and
18 washed with CH₂Cl₂ (20 mL). The filtrate was concentrated by rotary evaporation. The residue was
19 purified by column chromatography (1:1 hexane/EtOAc) to afford **S1e** (1.16 g, 96%) as a white solid.
20 TLC: *R_f* 0.48 (1:2 hexane/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 8.21–8.18 (m, 2H), 7.41–7.38 (m,
21 5H), 7.33 (s, 1H), 6.93 (d, *J* = 8.8 Hz, 2H), 4.99 (s, 2H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ
22 160.3, 134.1, 131.1, 130.6, 128.8, 128.6, 125.3, 114.5, 70.8, 55.5. HRMS (ESI) *m/z* calcd for
23 C₁₅H₁₆NO₂ [M+ H]⁺ 242.1176, found 242.1177.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 *(Z)*-*N*-(Cyclohexylmethylene)-1-phenylmethanamine oxide (**S1f**).⁴ *N*-(4-
39 Methoxybenzyl)hydroxylamine (493 mg, 4.00 mmol, 1.00 equiv), cyclohexylaldehyde (550 μL, 4.40
40 mmol, 1.10 equiv) and anhydrous MgSO₄ (530 mg, 4.40 mmol, 1.10 equiv) were suspended in
41 anhydrous toluene (12 mL). After stirring for 16.5 h at room temperature, the resulting suspension was
42 filtered and washed with CH₂Cl₂ (20 mL). The filtrate was concentrated by rotary evaporation. The
43 residue was recrystallized from hexane/EtOAc, and the mother liquor was further purified by column
44 chromatography (1:1 hexane/EtOAc) to afford **S1f** (858 mg, 99%) as a white solid. TLC: *R_f* 0.22 (1:2
45 hexane/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (m, 5H), 6.45 (d, *J* = 7.2 Hz, 1H), 4.84 (s, 2H),
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.97 (m, 1H), 1.85–1.82 (m, 2H), 1.68–1.64 (m, 3H), 1.40–1.29 (m, 2H), 1.25–1.06 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 143.2, 133.4, 129.2, 129.0, 128.9, 69.5, 35.2, 28.9, 26.1, 25.4.

General procedure for the synthesis of propargylic *N*-hydroxylamines **1a–s**.²⁰

To an oven-dried, 25-mL one-arm roundbottom flask, anhydrous Et_2O (12.0 mL), nitron (1.20 mmol, 1.20 equiv), ZnBr_2 (45.0 mg, 0.20 mmol, 0.20 equiv), alkyne (1.00 mmol, 1.00 equiv), *i*- Pr_2NEt (226 μL , 1.30 mmol, 1.30 equiv) and TMSOTf (217 μL , 1.20 mmol, 1.20 equiv) were added sequentially at room temperature. The heterogeneous mixture was stirred at room temperature for indicated time. The resulting suspension was filtered through a plug of silica gel (1 cm \times 5 cm), washed with Et_2O (50 mL), and concentrated by rotary evaporation. The crude product of the reaction was dissolved in MeOH (10 mL) with magnetic stirring, and treated with a *p*-toluenesulfonic acid (19.0 mg, 0.1 mmol). After completion of the TMS deprotection, the resulting mixture was concentrated by rotary evaporation. The residue was purified by column chromatography (hexanes/ EtOAc) to afford propargylic *N*-hydroxylamines **1a–s**.

N-Benzyl-*N*-(1,3-diphenylprop-2-yn-1-yl)hydroxylamine (**1a**).⁴ **1a** was prepared from phenylacetylene (110 μL , 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 2 h after the addition of *p*-toluenesulfonic acid. White solid (260 mg, 84%). TLC: R_f 0.25 (9:1 hexanes/ EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.64 (d, $J = 7.2$ Hz, 2H), 7.59–7.56 (m, 2H), 7.42–7.27 (m, 11H), 5.00 (s, 1H), 4.96 (brs, 1H), 4.07 (d, $J = 13.2$ Hz, 1H), 4.00 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.5, 137.1, 132.2, 129.9, 129.2, 128.7, 128.6, 128.5, 128.4, 128.3, 127.8, 122.9, 88.9, 84.6, 63.2, 60.6. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{20}\text{NO}$ [$\text{M} + \text{H}$]⁺ 314.1539, found 314.1542. IR (KBr film): 3229, 3062, 3030, 2905, 1489, 1453 cm^{-1} .

N-benzyl-*N*-(1-phenyl-3-(*p*-tolyl)prop-2-yn-1-yl)hydroxylamine (**1b**).²¹ **1b** was prepared from 4-ethynyltoluene (127 μL , 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 1 h after the

1 addition of *p*-toluenesulfonic acid. White solid (220 mg, 67%). TLC: R_f 0.37 (9:1 hexanes/EtOAc). ^1H
2 NMR (400 MHz, CDCl_3): δ 7.64 (d, $J = 7.6$ Hz, 2H), 7.47 (d, $J = 7.6$ Hz, 2H), 7.42–7.27 (m, 8H), 7.16
3 (d, $J = 8.0$ Hz, 2H), 5.00 (s, 1H), 4.88 (brs, 1H), 4.08 (d, $J = 13.2$ Hz, 1H), 4.00 (d, $J = 13.2$ Hz, 1H),
4 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 138.8, 137.7, 137.4, 132.1, 129.9, 129.3, 129.1, 128.6,
5 128.5, 128.3, 127.7, 119.9, 89.2, 83.9, 63.4, 60.7, 21.7. HRMS (ESI) m/z calculated for $\text{C}_{23}\text{H}_{22}\text{NO}$
6 [M+H] $^+$ 328.1696, found 328.1702. IR (KBr film): 3229, 3062, 3029, 2918, 1509, 1452 cm^{-1} .
7
8
9

10 *N*-Benzyl-*N*-(3-(3,5-dimethoxyphenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1c**). **1c** was prepared
11 from 1-ethynyl-3,5-dimethoxybenzene (162 mg, 1.00 mmol) and the (*Z*)-*N*-benzylidene-benzylamine-*N*-
12 oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 2 h. Then, the reaction mixture was stirred for an
13 additional 2 h after the addition of *p*-toluenesulfonic acid. White solid (373 mg, quantitative yield).
14 TLC: R_f 0.37 (5:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.62 (dd, $J = 8.8$ Hz, 1.2 Hz, 2H),
15 7.38–7.26 (m, 8H), 6.72 (d, $J = 2.4$ Hz, 2H), 6.48 (t, $J = 2.4$, 1H), 5.16 (brs, 1H), 4.96 (s, 1H), 4.03 (d, J
16 = 12.8 Hz, 1H), 3.98 (d, $J = 12.8$, 1H), 3.80 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 160.7, 137.4,
17 137.1, 129.9, 129.2, 128.6, 128.5, 128.4, 127.8, 124.2, 110.0, 102.1, 88.9, 84.3, 63.3, 61.4, 55.7. HRMS
18 (ESI) m/z calculated for $\text{C}_{24}\text{H}_{23}\text{NNaO}_3$ [M+Na] $^+$: 396.1570, found 396.1563. IR (KBr film): 3228,
19 3029, 2360, 1588, 1453, 1205 cm^{-1} . mp: 134–135 $^\circ\text{C}$.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 *N*-Benzyl-*N*-(3-(4-pentylphenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1d**).²² **1d** was prepared from
39 1-ethynyl-4-pentylbenzene (195 μL , 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**)
40 (253 mg, 1.20 mmol). Reaction time: 4 h. Then, the reaction mixture was stirred for an additional 1 h
41 after the addition of *p*-toluenesulfonic acid. White solid (360 mg, 94%). TLC: R_f 0.43 (9:1
42 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.65 (d, $J = 7.6$ Hz, 2H), 7.49 (d, $J = 8.0$ Hz, 2H),
43 7.42–7.27 (m, 8H), 7.17 (d, $J = 8.0$ Hz, 2H), 5.03 (s, 1H), 4.75 (brs, 1H), 4.11 (d, $J = 13.2$ Hz, 1H), 4.00
44 (d, $J = 13.2$ Hz, 1H), 2.62 (t, $J = 7.6$ Hz, 2H), 1.62 (quintet, $J = 7.6$ Hz, 2H), 1.37–1.29 (m, 4H), 0.90 (t,
45 $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 143.9, 137.7, 137.3, 132.1, 129.9, 129.1, 128.7, 128.6,
46 128.5, 128.3, 127.7, 120.1, 89.3, 83.8, 63.4, 60.8, 36.1, 31.6, 31.2, 22.7, 14.2. HRMS (ESI) m/z
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 calculated for $C_{27}H_{29}NNaO$ $[M+Na]^+$ 406.2141, found 406.2136. IR (KBr film): 2954, 2927, 2856,
2 1509, 1453 cm^{-1} .
3

4
5 *N*-Benzyl-*N*-(3-(4-fluorophenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1e**). **1e** was prepared from *p*-
6 fluorophenylacetylene (115 μ L, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253
7 mg, 1.20 mmol). Reaction time: 2 h. Then, the reaction mixture was stirred for an additional 1 h after
8 the addition of *p*-toluenesulfonic acid. White solid (330 mg, quantitative yield). TLC: R_f 0.49 (5:1
9 hexanes/EtOAc). 1H NMR (400 MHz, $CDCl_3$): δ 7.63 (d, $J = 8.8$ Hz, 2H), 7.55 (dd, $J = 8.8$ Hz, 5.6 Hz,
10 2H), 7.41–7.28 (m, 8H), 7.05 (t, $J = 8.8$ Hz, 2H), 4.98 (s, 1H), 4.05 (d, $J = 12.8$ Hz, 1H), 4.00 (d, $J =$
11 12.8 Hz, 1H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 162.8 (d, $J_{C-F} = 248.4$ Hz), 137.5, 137.2, 134.1 (d, $J_{C-F} =$
12 8.5 Hz), 129.9, 129.1, 128.6 128.5, 128.4, 127.8, 119.1 (d, $J_{C-F} = 3.1$ Hz), 115.8 (d, $J_{C-F} = 21.6$ Hz),
13 87.8, 84.4, 63.2, 60.6. ^{19}F NMR (376 MHz, $CDCl_3$): δ -110.8. HRMS (EI TOF) m/z calculated for
14 $C_{22}H_{19}FNO$ $[M+H]^+$ 332.1445, found 332.1443. IR (KBr film): 3240, 2903, 1600, 1505, 1229, 835, 697
15 cm^{-1} . mp: 134–136 $^{\circ}C$.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 *N*-Benzyl-*N*-(3-(3,4-dichlorophenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1f**). **1f** was prepared
32 from 3,4-dichlorophenylacetylene (171 mg, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide
33 (**S1a**) (253 mg, 1.20 mmol). Reaction time: 2 h. Then, the reaction mixture was stirred for an additional
34 1 h after the addition of *p*-toluenesulfonic acid. White solid (330 mg, 86%). TLC: R_f 0.43 (9:1
35 hexanes/EtOAc). 1H NMR (400 MHz, $CDCl_3$): δ 7.65 (d, $J = 1.6$ Hz, 1H), 7.60 (d, $J = 7.2$ Hz, 2H),
36 7.44–7.26 (m, 10H), 5.05 (brs, 1H), 4.97 (brs, 1H), 4.03 (d, $J = 13.2$ Hz, 1H), 3.97 (d, $J = 13.2$ Hz, 1H).
37 ^{13}C NMR (100 MHz, Acetone- d_6): δ 139.6, 139.2, 134.2, 133.0, 132.9, 132.5, 131.7, 130.1, 129.8, 129.1,
38 129.0, 128.7, 127.9, 124.7, 89.9, 85.9, 64.4, 61.7. HRMS (ESI) m/z calculated for $C_{22}H_{18}Cl_2NO$ $[M+H]^+$
39 382.0760, found 382.0759. IR (KBr film): 3233, 3029, 1738, 1473, 1217, 736, 697 cm^{-1} . mp: 133–136
40 $^{\circ}C$.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 *N*-benzyl-*N*-(1-phenyl-3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-yl)hydroxylamine (**1g**). **1g** was
55 prepared from *p*-(trifluoromethyl)phenyl acetylene (163 μ L, 1.00 mmol) and the (*Z*)-*N*-
56 benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 6 h. Then, the reaction
57
58
59
60

1 mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. White solid (267
2 mg, 70%). TLC: R_f 0.37 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.67 (d, $J = 8.0$ Hz,
3 2H), 7.64–7.60 (m, 4H), 7.42–7.28 (m, 8H), 5.03 (s, 1H), 4.95 (brs, 1H), 4.09 (d, $J = 13.2$ Hz, 1H), 4.00
4 2H), 7.64–7.60 (m, 4H), 7.42–7.28 (m, 8H), 5.03 (s, 1H), 4.95 (brs, 1H), 4.09 (d, $J = 13.2$ Hz, 1H), 4.00
5 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.1, 137.0, 132.4, 130.5 (q, $J_{\text{C-F}} = 32.5$ Hz),
6 129.8, 129.1, 128.7, 128.6, 128.5, 127.9, 126.8, 125.5 (q, $J_{\text{C-F}} = 3.9$ Hz), 124.1 (q, $J_{\text{C-F}} = 270.1$ Hz),
7 87.5, 87.4, 63.3, 60.9. ^{19}F NMR (376 MHz, CDCl_3): δ –63.2. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{F}_3\text{NO}$
8 $[\text{M}+\text{H}]^+$ 382.1413, found 382.1411. IR (KBr film): 3031, 2905, 1613, 1452, 758, 698 cm^{-1} . mp: 146–
9 148 $^\circ\text{C}$.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4-(3-(Benzyl(hydroxy)amino)-3-phenylprop-1-yn-1-yl)benzotrile (**1h**). **1k** was prepared from 4-ethynylbenzotrile (127 mg, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 2 h. Then, the reaction mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. Yellow solid (180 mg, 53%). TLC: R_f 0.36 (4:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.65 (s, 4H), 7.61 (d, $J = 7.2$ Hz, 2H), 7.42–7.28 (m, 8H), 5.02 (s, 1H), 4.05 (d, $J = 13.2$ Hz, 1H), 4.01 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 136.9, 132.7, 132.3, 129.8, 129.1, 128.8, 128.7, 128.6, 128.5, 127.9, 127.8, 118.6, 112.1, 89.7, 87.2, 63.4, 60.9. HRMS (ESI) m/z calculated for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$ 339.1492, found 339.1498. IR (KBr film): 3220, 2227, 1599, 1452, 846, 736 cm^{-1} . mp: 170–172 $^\circ\text{C}$.

Methyl 4-(3-(benzyl(hydroxy)amino)-3-phenylprop-1-yn-1-yl)benzoate (**1i**). **1i** was prepared from Methyl 4-ethynylbenzoate (160 mg, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. White solid (278 mg, 75%). TLC: R_f 0.31 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 8.03 (d, $J = 8.4$ Hz, 2H), 7.64–7.62 (m, 4H), 7.41–7.28 (m, 8H), 5.02 (s, 1H), 4.99 (brs, 1H), 4.06 (d, $J = 13.2$ Hz, 1H), 4.00 (d, $J = 13.2$ Hz, 1H), 3.93 (s, 3H). ^{13}C NMR (100 MHz, Acetone- d_6): δ 166.8, 139.6, 139.3, 132.8, 130.8, 130.4, 130.1, 129.8, 129.1, 129.0, 128.9, 128.7, 127.9, 90.7, 87.6, 64.5, 61.7, 52.6. HRMS (ESI) m/z calculated for $\text{C}_{24}\text{H}_{21}\text{NNaO}_3$

[M+Na]⁺ 394.1414, found 394.1415. IR (KBr film): 3452, 2951, 1722, 1276, 769, 697 cm⁻¹. mp: 145–147 °C.

N-benzyl-*N*-(1-phenylnon-2-yn-1-yl)hydroxylamine (**1j**).^{6a} **1j** was prepared from 1-octyne (148 μL, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 2 h. Then, the reaction mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. Colorless oil (260 mg, 81%). TLC: *R*_f 0.51 (5:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 8.8 Hz, 2H), 7.36–7.25 (m, 8H), 4.69 (s, 1H), 3.88 (s, 2H), 2.38 (td, *J* = 7.2 Hz, 2.0 Hz, 2H), 1.63 (quintet, *J* = 7.2 Hz, 2H), 1.48 (m, 2H), 1.36–1.30 (m, 4H), 0.91 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 138.0, 137.3, 129.9, 129.1, 128.5, 128.4, 128.0, 127.6, 89.7, 74.9, 62.7, 60.5, 31.5, 29.1, 28.9, 22.8, 19.2, 14.3. HRMS (ESI) *m/z* calcd for C₂₂H₂₈NO [M+H]⁺ 322.2165, found 322.2168. IR (KBr film): 3200, 2954, 2929, 2857, 1453 cm⁻¹.

N-Benzyl-*N*-(3-(6-methoxynaphthalen-2-yl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1k**). **1k** was prepared from 2-ethynyl-6-methoxynaphthalene (182 mg, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 1 h. Then, the reaction mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. White solid (225 mg, 57%). TLC: *R*_f 0.37 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 8.02 (s, 1H), 7.73–7.68 (m, 4H), 7.58 (dd, *J* = 8.4 Hz, 1.2 Hz, 1H), 7.45–7.25 (m, 8H), 7.16 (dd, *J* = 9.2 Hz, 2.8 Hz, 1H), 7.13 (d, *J* = 2.8 Hz, 1H), 5.07 (s, 1H), 4.84 (s, 1H), 4.16 (d, *J* = 13.2 Hz, 1H), 4.07 (d, *J* = 13.2 Hz, 1H), 3.93 (s, 3H). ¹³C NMR (100 MHz, C₆D₆): δ 159.3, 139.3, 138.9, 135.2, 132.6, 130.4, 130.2, 130.1, 129.9, 129.5, 129.0, 128.6, 128.3, 128.0, 127.6, 120.3, 118.9, 106.6, 89.8, 64.4, 61.8, 55.2. HRMS (ESI) *m/z* calculated for C₂₇H₂₄NO₂ [M+H]⁺ 394.1802, found 394.1797. IR (KBr film): 3234, 3060, 3029, 1628, 1601, 759, 737 cm⁻¹. mp: 148–150 °C.

N-Benzyl-*N*-(1-phenyl-3-(thiophen-3-yl)prop-2-yn-1-yl)hydroxylamine (**1l**). **1l** was prepared from 3-ethynylthiophene (99 μL, 1.00 mmol) and the (*Z*)-*N*-benzylidenebenzylamine-*N*-oxide (**S1a**) (253 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. White solid (278 mg, 87%). TLC: *R*_f 0.29 (9:1 hexanes/EtOAc). ¹H

1 NMR (400 MHz, CDCl₃): δ 7.63–7.61 (m, 2H), 7.55 (dd, *J* = 2.8 Hz, 1.2 Hz, 1H), 7.40–7.37 (m, 3H),
2 7.36–7.27 (m, 6H), 7.21 (dd, *J* = 5.2 Hz, 1.2 Hz, 1H), 4.96 (s, 1H), 4.04 (d, *J* = 13.2 Hz, 1H), 3.99 (d, *J*
3 = 13.2 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 137.5, 137.2, 130.4, 129.9, 129.4, 129.2, 128.6, 128.5,
4 128.3, 127.8, 125.5, 121.9, 84.3, 83.9, 63.3, 60.3. HRMS (ESI) *m/z* calculated for C₂₀H₁₈NOS [M+H]⁺
5 320.1104, found 320.1100. IR (KBr film): 3231, 3106, 3029, 2904, 1453, 1357 cm⁻¹. mp: 139–141 °C.
6
7

8
9
10
11 *N*-Benzyl-*N*-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)hydroxylamine (**1m**).²³ **1m** was prepared
12 from phenylacetylene (110 μL, 1.00 mmol) and the (*Z*)-*N*-(4-methoxybenzylidene)-1-
13 phenylmethanamine oxide (**S1b**) (290 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture
14 was stirred for an additional 1 h after the addition of *p*-toluenesulfonic acid. White solid (210 mg, 61%).
15 TLC: *R_f* 0.45 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.59–7.57 (m, 2H), 7.55 (d, *J* = 8.8
16 Hz, 2H), 7.40 (d, *J* = 7.2 Hz, 2H), 7.37–7.32 (m, 5H), 7.29 (d, *J* = 7.2 Hz, 1H), 6.92 (d, *J* = 8.8 Hz, 2H),
17 4.95 (brs, 1H), 4.02 (s, 2H), 3.81 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 159.7, 137.2, 132.1, 130.4,
18 130.0, 129.5, 128.6, 128.5, 128.4, 127.7, 123.0, 113.9, 88.7, 85.0, 62.7, 60.4, 55.5. HRMS (ESI) *m/z*
19 calcd for C₂₃H₂₂NO₂ [M+H]⁺ 344.1651, found 344.1649. IR (KBr film): 3231, 3062, 3030, 1511, 1251
20 cm⁻¹.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *N*-Benzyl-*N*-(1-(4-nitrophenyl)-3-phenylprop-2-yn-1-yl)hydroxylamine (**1n**).²¹ **1n** was prepared from
37 phenylacetylene (110 μL, 1.00 mmol) and the (*Z*)-*N*-(4-nitrobenzylidene)-1-phenylmethanamine oxide
38 (**S1c**) (308 mg, 1.20 mmol). Reaction time: 4 h. Then, the reaction mixture was stirred for an additional
39 1 h after the addition of *p*-toluenesulfonic acid. White solid (295 mg, 82%). TLC: *R_f* 0.40 (9:1
40 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 8.23 (dt, *J* = 8.8 Hz, 2.0 Hz, 2H), 7.83 (dt, *J* = 8.8 Hz,
41 2.0 Hz, 2H), 7.60–7.58 (m, 2H), 7.45–7.30 (m, 8H), 5.06, (s, 1H), 4.19 (d, *J* = 12.8 Hz, 1H), 4.13 (d, *J* =
42 12.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 147.2, 145.0, 136.5, 132.2, 129.9, 129.8, 129.2, 128.8,
43 128.7, 128.1, 123.7, 122.3, 90.3, 82.9, 62.6, 61.8. HRMS (ESI) *m/z* calcd for C₂₂H₁₉N₂O₃ [M+H]⁺
44 359.1390, found 359.1386. IR (KBr film): 3238, 3030, 1597, 1489 cm⁻¹.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

N-Benzyl-*N*-(4-methyl-1-phenylpent-1-yn-3-yl)hydroxylamine (**1o**).²¹ **1o** was prepared from phenylacetylene (55.0 μ L, 500 μ mol), (*Z*)-*N*-(2-methylpropylidene)-1-phenylmethanamine oxide (**S1d**) (106 mg, 600 μ mol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 4 h after the addition of *p*-toluenesulfonic acid. White solid (115 mg, 82%). TLC: R_f 0.40 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.52–7.49 (m, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.34–7.25 (m, 6H), 4.42 (s, 1H), 4.23 (d, J = 12.8 Hz, 1H), 3.89 (d, J = 12.8 Hz, 1H), 3.39 (d, J = 8.8 Hz, 1H), 2.14 (m, 1H), 1.13 (d, J = 6.8 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 137.7, 132.1, 129.6, 128.6, 128.5, 128.4, 127.6, 123.2, 88.0, 85.4, 66.5, 62.5, 31.1, 20.2, 20.0. HRMS (ESI) m/z calcd for C₁₉H₂₂NO [M+ H]⁺ 280.1696, found 280.1697. IR (KBr film): 3453, 2960, 1489, 1384 cm⁻¹.

N-(1,3-Diphenylprop-2-yn-1-yl)-*N*-(4-methoxybenzyl)hydroxylamine (**1p**).²¹ **1p** was prepared from phenylacetylene (110 μ L, 1.00 mmol) and the (*Z*)-*N*-benzylidene-1-(4-methoxyphenyl)methanamine oxide (**S1e**) (290 mg, 1.20 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 12 h after the addition of *p*-toluenesulfonic acid. White solid (355 mg, quantitative yield). TLC: R_f 0.30 (5:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, J = 6.8 Hz, 2H), 7.59–7.57 (m, 2H), 7.41–7.31 (m, 8H), 6.82 (dt, J = 8.8 Hz, 2.8 Hz, 2H), 5.02 (s, 1H), 4.06 (d, J = 13.2 Hz, 1H), 4.00 (d, J = 13.2 Hz, 1H), 3.80 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 159.3, 137.7, 132.2, 131.0, 129.2, 129.1, 128.7, 128.6, 128.5, 128.3, 122.9, 114.0, 89.0, 84.6, 63.1, 60.5, 55.5. HRMS (ESI) m/z calcd for C₂₃H₂₂NO₂ [M+H]⁺ 344.1645, found 344.1650. IR (KBr film): 3231, 3061, 2906, 1489, 1301 cm⁻¹.

N-(*tert*-Butyl)-*N*-(1,3-diphenylprop-2-yn-1-yl)hydroxylamine (**1q**). **1q** was prepared from phenylacetylene (550 μ L, 5.00 mmol) and *N*-*tert*-butylphenylnitron (1.06 g, 6.00 mmol). Reaction time: 16 h. Then, the reaction mixture was stirred for an additional 12 h after the addition of *p*-toluenesulfonic acid. Light yellow solid (1.10 g, 79%). TLC: R_f 0.47 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, J = 8.8 Hz, 2H), 7.51–7.48 (m, 2H), 7.39–7.29 (m, 6H), 5.20 (s, 1H), 4.34

(brs, 1H), 1.36 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): δ 140.4, 131.7, 128.5, 128.4, 128.3 (2C), 127.6, 123.3, 88.7, 87.2, 60.2, 56.8, 26.8. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{22}\text{NO}$ $[\text{M}+\text{H}]^+$ 280.1696, found 280.1698. IR (KBr film): 3532, 3457, 2971, 1597, 1490, 720, 650 cm^{-1} . mp: 76–79 $^\circ\text{C}$.

N-Benzyl-*N*-(1,3-dicyclohexylprop-2-yn-1-yl)hydroxylamine (**1r**). **1r** was prepared from cyclohexylacetylene 95% (230 μL , 1.00 mmol) and (*Z*)-*N*-(cyclohexylmethylene)-1-phenylmethanamine oxide (**S1f**) (261 mg, 1.20 mmol). Reaction time: 24 h. Then, the reaction mixture was stirred for an additional 2 h after the addition of *p*-toluenesulfonic acid. White solid (323 mg, 99%). TLC: R_f 0.25 (6:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.40–7.25 (m, 5H), 4.39 (s, 1H), 4.11 (d, $J = 12.8$ Hz, 1H), 3.79 (d, $J = 12.8$ Hz, 1H), 3.22 (d, $J = 4.0$ Hz, 1H), 2.55–2.51 (m, 1H), 2.09–0.86 (m, 21H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.8, 129.5, 128.5, 127.4, 93.3, 74.8, 64.9, 62.5, 40.3, 33.3, 33.2, 30.6 (2C), 29.3, 26.8, 26.3, 26.1, 25.0. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{32}\text{NO}$ $[\text{M}+\text{H}]^+$ 326.2478, found 326.2483.

IR (KBr film): 3534, 3462, 2927, 1604, 1495, 743, 699 cm^{-1} . mp: 76–78 $^\circ\text{C}$.

N-benzyl-*N*-(1-cyclohexyl-3-phenylprop-2-yn-1-yl)hydroxylamine (**1s**).⁴ **1s** was prepared from phenylacetylene (110 μL , 1.00 mmol) and (*Z*)-*N*-(cyclohexylmethylene)-1-phenylmethanamine oxide (**S1f**) (261 mg, 1.20 mmol). Reaction time: 16.5 h. Then, the reaction mixture was stirred for an additional 2.5 h after the addition of *p*-toluenesulfonic acid. White solid (272 mg, 85%). TLC: R_f 0.5 (7:1 hexanes/EtOAc). ^1H NMR (400 MHz, CDCl_3): δ 7.53 (dd, $J = 6.8$ Hz, 2.8 Hz, 2H), 7.42 (d, $J = 6.8$ Hz, 2H), 7.35–7.29 (m, 6H), 4.60 (brs, 1H), 4.20 (d, $J = 13.2$ Hz, 1H), 3.92 (d, $J = 13.2$ Hz, 1H), 3.47 (d, $J = 8.8$ Hz, 1H), 2.14–2.12 (m, 2H), 1.88–1.67 (m, 4H), 1.36–0.97 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3): δ 137.8, 132.1, 129.5, 128.6, 128.5, 128.4, 127.5, 123.2, 88.3, 85.3, 65.3, 62.5, 40.3, 30.8, 30.7, 26.8, 26.3, 26.1. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{26}\text{NO}$ $[\text{M}+\text{H}]^+$ 320.2009, found 320.2015. IR (KBr film): 3535, 3457, 2925, 1598, 1489, 756, 691 cm^{-1} . mp: 126–128 $^\circ\text{C}$. (Lit.⁴ 126–128 $^\circ\text{C}$.)

General procedure for the synthesis of 4-isoxazoline 2a–s.

1 (PPh₃)AuCl/AgOTf: In a 25 mL one-arm roundbottom flask, propargylic *N*-hydroxylamine (200
2 μmol), (PPh₃)AuCl (5.0 mg, 10.0 μmol, 5 mol%), and AgOTf (2.6 mg, 10.0 μmol, 5 mol%) were
3 dissolved in anhydrous toluene (4 mL) under Ar atmosphere. The resulting suspension was stirred at
4 room temperature (as shown in table 2). Upon completion of the reaction, the reaction mixture was
5 filtered through a plug of Celite, and rinsed with ether (20 mL). The filtrate was concentrated by rotary
6 evaporation. The residue was purified by column chromatography (19:1 hexanes/EtOAc).
7
8
9
10
11
12
13

14 (PPh₃)AuNTf₂: In a 25 mL one-arm roundbottom flask, propargylic *N*-hydroxylamine (200 μmol) and
15 (PPh₃)AuNTf₂ (7.4 mg, 10.0 μmol, 5 mol%) were dissolved in anhydrous toluene (4 mL) under Ar
16 atmosphere. The resulting suspension was stirred at room temperature (as shown in table 2). Upon
17 completion of the reaction, the reaction mixture was filtered through a plug of Celite, and rinsed with
18 ether (20 mL). The filtrate was concentrated by rotary evaporation. The residue was purified by column
19 chromatography (hexanes/EtOAc).
20
21
22
23
24
25
26
27

28 *2-Benzyl-3,5-diphenyl-2,3-dihydroisoxazole* (**2a**).^{4,21} **2a** was prepared from *N*-benzyl-*N*-(1,3-
29 diphenylprop-2-yn-1-yl)hydroxylamine (**1a**) (62.6 mg, 200 μmol). Purification by column
30 chromatography (98:2 hexanes/EtOAc) afforded **2a** as a yellow solid. Reaction time: 15 min, yield: 59.0
31 mg (94%) for (PPh₃)AuCl/AgOTf. Reaction time: 30 min, yield: 56.3 mg (90 %) for (PPh₃)AuNTf₂.
32 TLC: *R_f* 0.65 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.58–7.56 (m, 2H), 7.43 (d, *J* = 8.4
33 Hz, 2H), 7.37–7.23 (m, 11H), 5.42 (d, *J* = 2.4 Hz, 1H), 5.05 (d, *J* = 2.4 Hz, 1H), 4.43 (d, *J* = 12.8 Hz,
34 1H), 4.11 (d, *J* = 12.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 153.1, 142.3, 136.6, 129.8, 129.3, 128.9,
35 128.7, 128.6, 128.5, 127.8 (2C), 127.3, 125.9, 95.9, 73.8, 63.6. HRMS (ESI) *m/z* calcd for C₂₂H₂₀NO
36 [M+ H]⁺ 314.1539, found 314.1526. IR (KBr film): 3061, 1600, 1493, 771, 697 cm⁻¹. mp: 105–108 °C.
37 (Lit.⁴ 102–104 °C).
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 (*E*)-Chalcone (**3a**). TLC: *R_f* 0.62 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 8.03 (dt, *J* =
53 1.2 Hz, 6.8 Hz, 2H), 7.81 (d, *J* = 16.0 Hz, 1H), 7.66–7.64 (m, 2H), 7.61–7.56 (m, 2H), 7.53–7.49 (m,
54 2H), 7.44–7.42 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.7, 145.0, 138.4, 135.1, 133.0, 130.7,
55
56
57
58
59
60

129.2, 128.8, 128.7, 128.6, 122.3. HRMS (ESI) m/z calcd for $C_{15}H_{13}O$ $[M+H]^+$ 209.0961, found 209.0964. IR (KBr film): 3059, 1664, 1606, 1215, 746, 688 cm^{-1} .

2-Benzyl-3-phenyl-5-(p-tolyl)-2,3-dihydroisoxazole (2b). **2b** was prepared from *N*-benzyl-*N*-(1-phenyl-3-(*p*-tolyl)prop-2-yn-1-yl)hydroxylamine (**1b**) (65.4 mg, 200 μ mol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2b** as a yellow solid. Reaction time: 15 min, yield: 53.0 mg (81%) for $(PPh_3)AuCl/AgOTf$. Reaction time: 15 min, yield: 52.7 mg (79 %) for $(PPh_3)AuNTf_2$. TLC: R_f 0.74 (9:1 hexanes/EtOAc). 1H NMR (400 MHz, C_6D_6): δ 7.47 (dt, $J = 8.0$ Hz, 2.0 Hz, 2H), 7.40 (dm, $J = 8.0$ Hz, 2H), 7.36 (dm, $J = 8.0$ Hz, 2H), 7.17–7.12 (m, 4H), 7.09–7.05 (m, 2H), 6.88 (d, $J = 8.0$ Hz, 2H), 5.11 (d, $J = 2.8$ Hz, 1H), 4.87 (d, $J = 2.8$ Hz, 1H), 4.33 (d, $J = 13.2$ Hz, 1H), 3.92 (d, $J = 13.2$ Hz, 1H), 2.01 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 153.7, 143.6, 139.5, 138.0, 130.1, 129.8, 129.2, 129.0, 128.2, 128.1, 128.0, 127.2, 126.6, 96.1, 75.0, 64.2, 21.7. HRMS (EI) m/z calcd for $C_{23}H_{21}NO$ $[M]^+$ 327.1623, found 327.1625. IR (KBr film): 3028, 1653, 1510, 759, 731 cm^{-1} .

2-Benzyl-5-(3,5-dimethoxyphenyl)-3-phenyl-2,3-dihydroisoxazole (2c). **2c** was prepared from *N*-benzyl-*N*-(3-(3,5-dimethoxyphenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1c**) (74.6 mg, 200 μ mol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2c** as a pale yellow solid. Reaction time: 10 min, yield: 74.6 mg (99%) for $(PPh_3)AuCl/AgOTf$. Reaction time: 15 min, yield: 67.1 mg (90%) for $(PPh_3)AuNTf_2$. TLC: R_f 0.54 (5:1 hexanes/EtOAc). 1H NMR (400 MHz, C_6D_6): δ 7.39–7.36 (m, 4H), 7.17–7.01 (m, 6H), 6.92 (d, $J = 2.4$ Hz, 2H), 6.54 (t, $J = 2.4$ Hz, 1H), 5.13 (d, $J = 3.2$ Hz, 1H), 4.86 (d, $J = 3.2$ Hz, 1H), 4.34 (d, $J = 13.2$ Hz, 1H), 3.93 (d, $J = 13.2$ Hz, 1H), 3.25 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 161.9, 153.7, 143.4, 137.8, 131.8, 130.2, 129.2, 128.9, 128.2, 128.1, 127.9, 104.8, 102.6, 97.6, 74.8, 64.1, 55.3. HRMS (ESI) m/z calculated for $C_{24}H_{24}NO_3$ $[M+H]^+$ 374.1751, found 374.1758. IR (KBr film): 3017, 2360, 1592, 1215, 698, 668 cm^{-1} .

2-Benzyl-5-(4-pentylphenyl)-3-phenyl-2,3-dihydroisoxazole (2d).¹⁵ **2d** was prepared from *N*-benzyl-*N*-(3-(4-pentylphenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1d**) (76.6 mg, 200 μ mol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2d** as a yellow syrup. Reaction time: 5 min, yield: 58.0 mg (76%) for $(PPh_3)AuCl/AgOTf$. Reaction time: 15 min, yield: 62.0 mg (81 %) for

(PPh₃)AuNTf₂. TLC: *R_f* 0.60 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, C₆D₆): δ 7.50 (dt, *J* = 8.4 Hz, 1.6 Hz, 2H), 7.41–7.35 (m, 4H), 7.17–7.02 (m, 6H), 6.95 (d, *J* = 8.4 Hz, 2H), 5.13 (d, *J* = 3.2 Hz, 1H), 4.87 (d, *J* = 3.2 Hz, 1H), 4.34 (d, *J* = 13.2 Hz, 1H), 3.92 (d, *J* = 13.2 Hz, 1H), 2.38 (t, *J* = 7.6 Hz, 2H), 1.45 (quintet, *J* = 7.6 Hz, 2H), 1.25–1.13 (m, 4H), 0.83 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 153.7, 144.6, 143.6, 138.0, 130.1, 129.2, 129.1, 129.0, 128.2, 128.1, 128.0, 127.5, 126.7, 96.2, 74.9, 64.2, 36.4, 32.1, 31.8, 23.3, 14.7. HRMS (ESI) *m/z* calcd for C₂₇H₃₀NO [M+H]⁺ 384.2322, found 384.2329. IR (KBr film): 3061, 2928, 1652, 770, 733 cm⁻¹.

2-Benzyl-5-(4-fluorophenyl)-3-phenyl-2,3-dihydroisoxazole (2e). **2e** was prepared from *N*-benzyl-*N*-(3-(4-fluorophenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1e**) (66.2 mg, 200 μmol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2e** as a yellow oil. Reaction time: 10 min, yield: 65.0 mg (98%) for (PPh₃)AuCl/AgOTf. Reaction time: 15 min, yield: 52.3 mg (79 %) for (PPh₃)AuNTf₂. TLC: *R_f* 0.65 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, C₆D₆): δ 7.38 (dd, *J* = 8.8 Hz, 1.2 Hz, 2H), 7.34 (dd, *J* = 8.8 Hz, 1.2 Hz, 2H), 7.24 (dd, *J* = 8.8 Hz, 5.2 Hz, 2H), 7.18–7.13 (m, 4H), 7.10–7.05 (m, 2H), 6.65 (tt, *J* = 8.8 Hz, 2.0 Hz, 2H), 4.96 (d, *J* = 2.8 Hz, 1H), 4.83 (d, *J* = 2.8 Hz, 1H), 4.27 (d, *J* = 13.2 Hz, 1H), 3.89 (d, *J* = 13.2 Hz, 1H). ¹³C NMR (100 MHz, C₆D₆): δ 163.8 (d, *J_{CF}* = 247.6 Hz), 152.6, 143.3, 137.8, 130.0, 129.2, 129.1, 128.5, 128.5, 128.5, 128.2, 127.9, 126.0 (d, *J_{CF}* = 3.9 Hz), 116.0 (d, *J_{CF}* = 21.6 Hz), 96.7 (d, *J_{CF}* = 1.6 Hz), 96.7, 75.0, 64.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -111.9. HRMS (EI) *m/z* calcd for C₂₂H₁₈FNO [M]⁺ 331.1372, found 331.1367. IR (KBr film): 3029, 1602, 1510, 733, 697 cm⁻¹.

2-Benzyl-5-(3,4-dichlorophenyl)-3-phenyl-2,3-dihydroisoxazole (2f). **2f** was prepared from *N*-benzyl-*N*-(3-(3,4-dichlorophenyl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1f**) (76.4 mg, 200 μmol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2f** as a pale yellow solid. Reaction time: 40 min, yield: 74.0 mg (97%) for (PPh₃)AuCl/AgOTf. Reaction time: 60 min, yield: 62.6 mg (82%) for (PPh₃)AuNTf₂. TLC: *R_f* 0.61 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, C₆D₆): δ 7.46 (d, *J* = 2.0 Hz, 1H), 7.33 (dt, *J* = 8.0 Hz, 1.6 Hz, 2H), 7.29 (dt, *J* = 8.0 Hz, 1.6 Hz, 2H), 7.18–7.06 (m, 6H), 6.93 (dd, *J* = 8.0 Hz, 2.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 4.83 (d, *J* = 2.8 Hz, 1H), 4.77 (d, *J* =

2.8 Hz, 1H), 4.20 (d, $J=13.2$ Hz, 1H), 3.84 (d, $J=13.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 151.0, 141.7, 136.3, 133.1, 132.9, 130.6, 129.7, 128.9, 128.8, 128.6, 128.0, 127.9, 127.8, 127.2, 125.1, 97.8, 73.9, 63.6. HRMS (EI) m/z calcd for $\text{C}_{22}\text{H}_{17}\text{Cl}_2\text{NO}$ $[\text{M}]^+$ 381.0687, found 381.0683. IR (KBr film): 3062, 1651, 1468, 1046, 732, 676 cm^{-1} . mp: 88–89 $^\circ\text{C}$.

2-Benzyl-3-phenyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydroisoxazole (2g). **2g** was prepared from *N*-benzyl-*N*-(1-phenyl-3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-yl)hydroxylamine (**1g**) (76.2 mg, 200 μmol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2g** as a white solid. Reaction time: 30 min, yield: 62.2 mg (82%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 60 min, yield: 72.4 mg (95 %) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.68 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 7.36 (dt, $J = 8.0$ Hz, 1.6 Hz, 2H), 7.33 (dt, $J = 8.0$ Hz, 1.6 Hz, 2H), 7.24–7.14 (m, 8H), 7.11–7.06 (m, 2H), 5.03 (d, $J = 2.8$ Hz, 1H), 4.82 (d, $J = 2.8$ Hz, 1H), 4.24 (d, $J = 13.2$ Hz, 1H), 3.86 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, C_6D_6): δ 152.1, 142.9, 137.6, 132.9 (q. $J_{\text{CF}} = 1.6$ Hz), 131.3, 130.9, 130.0, 129.3, 129.1, 128.3 (q. $J_{\text{CF}} = 20.9$ Hz), 127.9, 126.7, 126.0 (q. $J_{\text{CF}} = 3.9$ Hz), 125.2 (q. $J_{\text{CF}} = 270.9$ Hz), 99.3, 74.9, 64.1. ^{19}F NMR (376 MHz, CDCl_3): δ –62.8 HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$ 382.1413, found 382.1414. IR (KBr film): 3063, 1494, 1125, 731, 697 cm^{-1} . mp: 124–127 $^\circ\text{C}$.

4-(2-Benzyl-3-phenyl-2,3-dihydroisoxazol-5-yl)benzotrile (2h). **2h** was prepared from 4-(3-(benzyl(hydroxy)amino)-3-phenylprop-1-yn-1-yl)benzotrile (**1h**) (67.6 mg, 200 μmol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2h** as a white solid. Reaction time: 30 min, yield: 46.0 mg (68%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 60 min, yield: 47.3 mg (70 %) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.65 (4:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 7.33 (dt, $J = 8.0$ Hz, 1.6 Hz, 2H), 7.29 (dt, $J = 8.0$ Hz, 1.6 Hz, 2H), 7.18–7.13 (m, 4H), 7.10–7.03 (m, 2H), 7.02 (dt, $J = 8.8$ Hz, 2.0 Hz, 2H), 6.87 (dt, $J = 8.8$ Hz, 2.0 Hz, 2H), 4.97 (d, $J = 2.8$ Hz, 1H), 4.78 (d, $J = 2.8$ Hz, 1H), 4.18 (d, $J = 13.2$ Hz, 1H), 3.82 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 151.4, 141.4, 136.2, 133.1, 132.4, 129.7, 128.8, 128.6, 128.0, 127.9, 127.2, 126.4, 118.7, 112.5, 99.7, 74.0, 63.6. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$ 339.1492, found 339.1497. IR (KBr film): 3061, 3029, 2226, 1607, 738, 697 cm^{-1} . mp: 118–120 $^\circ\text{C}$.

Methyl 4-(2-benzyl-3-phenyl-2,3-dihydroisoxazol-5-yl)benzoate (2i). **2i** was prepared from methyl 4-(3-(benzyl(hydroxy)amino)-3-phenylprop-1-yn-1-yl)benzoate (**1i**) (74.2 mg, 200 μ mol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2i** as a white solid. Reaction time: 45 min, yield: 59.0 mg (80%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 60 min, yield: 57.9 mg (78 %) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.50 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 8.02 (dt, $J = 8.8$ Hz, 1.6 Hz, 2H), 7.41 (dt, $J = 8.8$ Hz, 1.6 Hz, 2H), 7.36 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 7.17–7.12 (m, 4H), 7.10–7.05 (m, 2H), 5.08 (d, $J = 2.8$ Hz, 1H), 4.82 (d, $J = 2.8$ Hz, 1H), 4.25 (d, $J = 13.2$ Hz, 1H), 3.85 (d, $J = 13.2$ Hz, 1H), 3.44 (s, 3H). ^{13}C NMR (100 MHz, C_6D_6): δ 166.6, 152.6, 142.9, 137.7, 133.8, 131.4, 130.5, 130.0, 129.2, 129.1, 128.3, 128.2, 127.9, 126.4, 99.5, 74.9, 64.1, 52.1. HRMS (EI) m/z calcd for $\text{C}_{24}\text{H}_{21}\text{NO}_3$ $[\text{M}]^+$ 371.1521, found 371.1516. IR (KBr film): 3061, 3028, 2950, 1720, 1242, 772, 697 cm^{-1} . mp: 146–147 $^\circ\text{C}$.

2-Benzyl-5-hexyl-3-phenyl-2,3-dihydroisoxazole (2j).¹⁴ **2j** was prepared from *N*-benzyl-*N*-(1-phenylnon-2-yn-1-yl)hydroxylamine (**1j**) (64.2 mg, 200 μ mol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2j** as a yellow oil. Reaction time: 10 min, yield: 56.0 mg (87%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 10 min, yield: 53.3 mg (83 %) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.57 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 7.38 (d, $J = 8.0$ Hz, 2H), 7.37 (d, $J = 8.0$ Hz, 2H), 7.21–7.17 (m, 2H), 7.13–7.04 (m, 4H), 4.76 (s, 1H), 4.49 (m, 1H), 4.28 (d, $J = 13.2$ Hz, 1H), 3.89 (d, $J = 13.2$ Hz, 1H), 2.03 (t, $J = 7.6$ Hz, 2H), 1.40 (quintet, $J = 7.6$ Hz, 2H), 1.23–1.09 (m, 6H), 0.85 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, C_6D_6): δ 156.2, 144.3, 138.2, 129.9, 129.1, 128.9, 128.0, 127.9, 127.8, 96.0, 74.4, 64.3, 32.3, 29.6, 27.7, 26.8, 23.4, 14.7. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{28}\text{NO}$ $[\text{M}+\text{H}]^+$ 322.2165, found 322.2169. IR (KBr film): 3062, 2954, 2927, 1453, 771, 669 cm^{-1} .

2-Benzyl-5-(6-methoxynaphthalen-2-yl)-3-phenyl-2,3-dihydroisoxazole (2k). **2k** was prepared from *N*-benzyl-*N*-(3-(6-methoxynaphthalen-2-yl)-1-phenylprop-2-yn-1-yl)hydroxylamine (**1k**) (78.6 mg, 200 μ mol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2k** as a yellow solid. Reaction time: 10 min, yield: 55.0 mg (70%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 30 min, yield: 61.0 mg (78%) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.54 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 8.05 (s,

1H), 7.59 (dd, $J = 8.8$ Hz, 1.2 Hz, 1H), 7.49 (d, $J = 8.8$ Hz, 1H), 7.43 (t, $J = 7.6$ Hz, 4H), 7.33 (d, $J = 8.8$ Hz, 1H), 7.20–7.16 (m, 3H), 7.11–7.01 (m, 4H), 6.85 (d, $J = 1.2$ Hz, 1H), 5.25 (d, $J = 2.4$ Hz, 1H), 4.94 (d, $J = 2.4$ Hz, 1H), 4.41 (d, $J = 13.2$ Hz, 1H), 3.98 (d, $J = 13.2$ Hz, 1H), 3.34 (s, 3H). ^{13}C NMR (100 MHz, C_6D_6): δ 159.3, 153.9, 143.6, 138.0, 135.8, 130.8, 130.1, 129.5, 129.2, 129.1, 129.0, 128.1, 128.0, 127.6, 125.9, 125.1, 125.0, 120.1, 106.7, 96.9, 75.1, 64.2, 55.2. HRMS (ESI) m/z calcd for $\text{C}_{27}\text{H}_{24}\text{NO}_2$ $[\text{M}+\text{H}]^+$ 394.1802, found 394.1806. IR (KBr film): 3060, 3028, 2360, 1625, 751, 697 cm^{-1} . mp: 121–123 $^\circ\text{C}$.

2-Benzyl-3-phenyl-5-(thiophen-3-yl)-2,3-dihydroisoxazole (2l). **2l** was prepared from *N*-benzyl-*N*-(1-phenyl-3-(thiophen-3-yl)prop-2-yn-1-yl)hydroxylamine (**1l**) (63.8 mg, 200 μmol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2l** as a white solid. Reaction time: 5 min, yield: 48.0 mg (75%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 15 min, yield: 50.0 mg (78%) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.72 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 7.37 (d, $J = 7.2$ Hz, 2H), 7.33 (d, $J = 7.2$ Hz, 2H), 7.17–7.12 (m, 5H), 7.10–7.04 (m, 2H), 6.93 (dd, $J = 5.2$ Hz, 1.2 Hz, 1H), 6.72 (dd, $J = 5.2$ Hz, 3.2 Hz, 1H), 4.92 (d, $J = 2.8$ Hz, 1H), 4.81 (d, $J = 2.8$ Hz, 1H), 4.29 (d, $J = 13.2$ Hz, 1H), 3.87 (d, $J = 13.2$ Hz, 1H). ^{13}C NMR (100 MHz, C_6D_6): δ 150.0, 143.4, 137.9, 131.0, 130.1, 129.2, 129.0, 128.2, 128.1, 127.9, 126.6, 126.4, 123.7, 96.7, 74.8, 64.2. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{18}\text{NOS}$ $[\text{M}+\text{H}]^+$ 320.1104, found 320.1108. IR (KBr film): 3107, 3028, 1659, 1453, 787, 657 cm^{-1} . mp: 85–88 $^\circ\text{C}$.

2-Benzyl-3-(4-methoxyphenyl)-5-phenyl-2,3-dihydroisoxazole (2m). **2m** was prepared from *N*-benzyl-*N*-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)hydroxylamine (**1m**) (68.6 mg, 200 μmol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2m** as a yellow solid. Reaction time: 15 min, yield: 68.0 mg (99%) for $(\text{PPh}_3)\text{AuCl}/\text{AgOTf}$. Reaction time: 20 min, yield: 63.0 mg (92%) for $(\text{PPh}_3)\text{AuNTf}_2$. TLC: R_f 0.52 (9:1 hexanes/EtOAc). ^1H NMR (400 MHz, C_6D_6): δ 7.53–7.51 (m, 2H), 7.41 (d, $J = 6.8$ Hz, 2H), 7.26 (dt, $J = 8.8$ Hz, 2.4 Hz, 2H), 7.18–7.14 (m, 2H), 7.10 (dt, $J = 7.6$ Hz, 1.2 Hz, 1H), 7.04–7.00 (m, 3H), 6.78 (dt, $J = 8.8$ Hz, 2.4 Hz), 5.14 (d, $J = 2.8$ Hz, 1H), 4.87 (d, $J = 2.8$ Hz, 1H), 4.33 (d, $J = 13.2$ Hz, 1H), 3.94 (d, $J = 13.2$ Hz, 1H), 3.27 (s, 3H). ^{13}C NMR (100 MHz, C_6D_6): δ 160.2, 153.5, 138.0, 135.4, 130.1, 130.0, 129.5, 129.3, 129.1, 129.0, 128.1, 126.6, 114.7, 97.2, 74.6,

64.0, 55.3. HRMS (EI) m/z calcd for $C_{23}H_{21}NO_2$ $[M]^+$ 343.1572, found 343.1564. IR (KBr film): 3062, 3029, 2836, 1653, 1608, 763, 698 cm^{-1} . mp: 68–70 °C.

2-Benzyl-3-(4-nitrophenyl)-5-phenyl-2,3-dihydroisoxazole (2n). **2n** was prepared from *N*-benzyl-*N*-(1-(4-nitrophenyl)-3-phenylprop-2-yn-1-yl)hydroxylamine (**1n**) (71.6 mg, 200 μ mol). Purification by column chromatography (97:3 hexanes/EtOAc) afforded **2n** as a brown solid. Reaction time: 10 min, yield: 71.0 mg (99%) for $(PPh_3)AuCl/AgOTf$. Reaction time: 15 min, yield: 61.0 mg (85%) for $(PPh_3)AuNTf_2$. TLC: R_f 0.60 (9:1 hexanes/EtOAc). 1H NMR (400 MHz, C_6D_6): δ 7.81 (dt, $J = 8.8$ Hz, 2.0 Hz, 2H), 7.49–7.47 (m, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.14–7.03 (m, 6H), 6.99 (dt, $J = 8.0$ Hz, 2.0 Hz, 2H), 4.91 (d, $J = 2.8$ Hz, 1H), 4.63 (d, $J = 2.8$ Hz, 1H), 4.28 (d, $J = 12.8$ Hz, 1H), 3.77 (d, $J = 12.8$ Hz, 1H). ^{13}C NMR (100 MHz, C_6D_6): δ 154.3, 149.9, 148.1, 137.1, 130.8, 130.1, 130.0, 129.3, 129.2, 129.1, 128.1, 126.6, 124.2, 95.3, 73.5, 63.9. HRMS (EI) m/z calcd for $C_{22}H_{18}N_2O_3$ $[M]^+$ 358.1317, found 358.1318. IR (KBr film): 3062, 3030, 1519, 734, 696 cm^{-1} . mp: 120–122 °C.

2-Benzyl-3-isopropyl-5-phenyl-2,3-dihydroisoxazole (2o).^{4, 12} **2o** was prepared from *N*-benzyl-*N*-(4-methyl-1-phenylpent-1-yn-3-yl)hydroxylamine (**1o**) (55.8 mg, 200 μ mol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded **2o** as a colorless oil. Reaction time: 30 min, yield: 50.7 mg (91%) for $(PPh_3)AuCl/AgOTf$. Reaction time: 15 min, yield: 49.0 mg (88%) for $(PPh_3)AuNTf_2$. TLC: R_f 0.62 (9:1 hexanes/EtOAc). 1H NMR (400 MHz, C_6D_6): δ 7.50 (dt, $J = 7.6$ Hz, 1.6 Hz, 2H), 7.41 (d, $J = 8.4$ Hz, 2H), 7.19 (d, $J = 8.4$ Hz, 2H), 7.10 (tt, $J = 7.6$ Hz, 1.6 Hz, 1H), 7.06–6.95 (m, 3H), 5.02 (d, $J = 2.8$ Hz, 1H), 4.20 (d, $J = 13.2$ Hz, 1H), 3.68 (d, $J = 13.2$ Hz, 1H), 3.51 (dd, $J = 6.4$ Hz, 2.8 Hz, 1H), 1.66 (octet, $J = 6.4$ Hz, 1H), 0.91 (d, $J = 6.4$ Hz, 3H), 0.88 (d, $J = 6.4$ Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 153.8, 138.2, 130.3, 130.2, 129.3, 129.0, 128.9, 128.0, 126.5, 93.9, 77.2, 64.7, 34.6, 19.0, 18.9. HRMS (ESI) m/z calcd for $C_{19}H_{22}NO$ $[M+H]^+$ 280.1696, found 280.1699. IR (KBr film): 3062, 3029, 2957, 2360, 1653, 1494, 1295, 1070, 696 cm^{-1} .

2-(4-Methoxybenzyl)-3,5-diphenyl-2,3-dihydroisoxazole (2p). **2p** was prepared from *N*-(1,3-diphenylprop-2-yn-1-yl)-*N*-(4-methoxybenzyl)hydroxylamine (**1p**) (68.6 mg, 200 μ mol). Purification by column chromatography (95:5 hexanes/EtOAc) afforded **2p** as a yellow solid. Reaction time: 30 min,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
yield: 57.3 mg (84%) for (PPh₃)AuCl/AgOTf. Reaction time: 60 min, yield: 56.0 mg (82%) for
(PPh₃)AuNTf₂. TLC: *R_f* 0.57 (5:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.59–7.56 (m, 2H),
7.39–7.22 (m, 10H), 6.88 (dt, *J* = 8.8 Hz, 2.8 Hz, 2H), 5.42 (d, *J* = 2.8 Hz, 1H), 5.05 (d, *J* = 2.8 Hz, 1H),
4.38 (d, *J* = 12.8 Hz, 1H), 4.06 (d, *J* = 12.8 Hz, 1H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ
159.3, 153.0, 142.3, 131.1, 129.2, 129.0, 128.7, 128.6, 128.5, 127.7, 127.3, 125.9, 113.9, 95.8, 73.4,
62.9, 55.4. HRMS (ESI) *m/z* calcd for C₂₃H₂₂NO₂ [M+H]⁺ 344.1645, found 344.1647. IR (KBr film):
2360, 1611, 1512, 1248, 697 cm⁻¹. mp: 77–79 °C.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
2-(tert-Butyl)-3,5-diphenyl-2,3-dihydroisoxazole (2q).¹⁰ **2q** was prepared from *N-(tert-butyl)-N-(1,3-*
diphenylprop-2-yn-1-yl)hydroxylamine (1q) (56.0 mg, 200 μmol). Purification by column
chromatography (98:2 hexanes/EtOAc) afforded **2q** as a colorless oil. Reaction time: 15 min, yield: 51.0
mg (91%) for (PPh₃)AuCl/AgOTf. Reaction time: 10 min, yield: 55.4 mg (99%) for (PPh₃)AuNTf₂.
TLC: *R_f* 0.75 (9:1 hexanes/EtOAc). ¹H NMR (400 MHz, C₆D₆): δ 7.52 (dd, *J* = 8.0 Hz, 1.6 Hz, 2H),
7.47 (dd, *J* = 8.0 Hz, 1.6 Hz, 2H), 7.20 (t, *J* = 7.6 Hz, 2H), 7.11–7.01 (m, 4H), 5.14 (d, *J* = 2.8 Hz, 1H),
5.01 (d, *J* = 2.8 Hz, 1H), 1.15 (s, 9H). ¹³C NMR (100 MHz, C₆D₆): δ 153.4, 145.9, 129.8, 129.4, 129.2,
129.1, 128.1, 127.8, 126.4, 98.3, 69.6, 61.1, 25.7. HRMS (ESI) *m/z* calcd for C₁₉H₂₂NO [M+H]⁺
280.1696, found 280.1697. IR (KBr film): 3027, 2973, 1656, 1493, 1449 cm⁻¹.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2-Benzyl-3,5-dicyclohexyl-2,3-dihydroisoxazole (2r). **2r** was prepared from *N-benzyl-N-(1,3-*
dicyclohexylprop-2-yn-1-yl)hydroxylamine (1r) (65.1 mg, 200 μmol). Purification by column
chromatography (15:1 hexanes/EtOAc) afforded **2r** as a yellow solid. Reaction time: 10 min, yield: 37.3
mg (58%) for (PPh₃)AuCl/AgOTf. Reaction time: 20 min, yield: 53.0 mg (82%) for (PPh₃)AuNTf₂.
TLC: *R_f* 0.57 (15:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 7.39–7.26 (m, 5H), 4.46 (d, *J* = 1.6
Hz, 1H), 4.08 (d, *J* = 12.8 Hz, 1H), 3.71 (d, *J* = 12.8 Hz, 1H), 3.44 (dd, *J* = 6.8 Hz, 1.6 Hz, 1H), 2.11–
1.54 (m, 11H), 1.26–0.69 (m, 11H). ¹³C NMR (100 MHz, CDCl₃): δ 159.5, 137.4, 129.9, 128.4, 127.5,
90.5, 75.1, 64.1, 43.8, 35.6, 31.2, 31.0, 29.3, 29.1, 26.8, 26.4, 26.2, 26.1. HRMS (ESI) *m/z* calcd for
C₂₂H₃₂NO [M+H]⁺ 326.2478, found 326.2483. IR (KBr film): 3030, 2925, 1668, 1496, 1450 cm⁻¹. mp:
60–62 °C.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2-Benzyl-3-cyclohexyl-5-phenyl-2,3-dihydroisoxazole (2s).⁴ **2s** was prepared from *N*-(benzyl)-*N*-(1-cyclohexyl-3-phenylprop-2-yn-1-yl)hydroxylamine (**1s**) (63.9 mg, 200 μmol). Purification by column chromatography (60:1 hexanes/EtOAc) afforded **2s** as a yellow solid. Reaction time: 60 min, yield: 62.8 mg (98%) for (PPh₃)AuCl/AgOTf. Reaction time: 20 min, yield: 55.5 mg (87%) for (PPh₃)AuNTf₂. ¹H NMR (400 MHz, CDCl₃): δ .53 (d, *J* = 7.2 Hz, 2H), 7.43(d, *J* = 7.2 Hz, 2H), 7.38–7.28 (m, 6H), 5.32 (d, *J* = 2.8 Hz, 1H), 4.25 (d, *J* = 12.8 Hz, 1H), 3.84 (d, *J* = 12.8 Hz, 1H), 3.68 (dd, *J* = 6.8 Hz, 2.8 Hz, 2H), 1.90–1.87 (m, 1H), 1.76–1.62 (m, 4H), 1.46–1.37 (m, 1H), 1.30–0.94 (m, 4H) 0.87–0.76 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 152.4, 137.0, 130.1, 129.4, 128.9, 128.5, 128.4, 127.6, 125.8, 94.1, 75.8, 64.1, 43.7, 29.5, 29.2, 26.7, 26.3, 26.2. HRMS (ESI) *m/z* calcd for C₂₂H₂₆NO [M+H]⁺ 320.2009, found 320.2014. IR (KBr film): 3062, 2923, 1652, 1494, 1448 cm⁻¹. mp: 90–92°C. (Lit.⁴ 88–91 °C).

Synthesis of chiral 4-isoxazoline (**S**)-**2a**.

(R)-*N*-Benzyl-*N*-(1,3-diphenylprop-2-yn-1-yl)hydroxylamine (**R-1a**).^{23,24} (**R**)-**1a** was prepared according to the previously reported procedure.^{23,24} A solution of dimethylzinc (1.2 M) in toluene (1.3 mL, 1.6 mmol) was added dropwise to a solution of di-(*t*-butyl) (*R,R*)-tartrate [(*R,R*)-DTBT] (52.5 mg, 0.2 mmol) in toluene (6 mL) at 0 °C under an Ar atmosphere. After the reaction mixture was stirred for 10 min, a solution of racemic *N*-benzyl-*N*-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)hydroxylamine (**1m**) (68.7 mg, 0.1 mmol) in toluene (6 mL) was added dropwise. The mixture was stirred for 10 min, and a solution of nitron **S1a** (121 mg, 1.0 mmol) in toluene (8 mL) and phenylacetylene (112 μL, 1.0 mmol) were added dropwise. After stirred for 18 h at 0 °C, the mixture was quenched with NH₄Cl (pH = 4-5) at 0 °C. The organic layer was separated and extracted with EtOAc (4 × 50 mL), dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentrated by rotary evaporation. The residue was purified by column chromatography (9:1 hexanes/EtOAc) to afford (**R**)-**1a** as a white solid (213 mg, 68%). The spectral data matched to those of **1a**. Chiral HPLC Method: Phenomenex Lux 5 μ Cellulose-1 column 250 × 4.6 mm; Injection volume, 5 μL; Flow rate, 1.0 mL/min; Elution method, *i*-PrOH/hexane 2.4/97.6 isocratic (0–45 min); UV detection at 254 nm; *t*₁ = 11.2 min (major isomer), *t*₂ = 12.4 min (minor isomer): [α]_D^{20.0} +41.2 (c 0.6, MeOH), 84% ee.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*S*)-2-Benzyl-3,5-diphenyl-2,3-dihydroisoxazole (*S*-**2a**).¹⁵ (*S*-**2a**) was prepared from *N*-benzyl-*N*-(1,3-diphenylprop-2-yn-1-yl)hydroxylamine (*R*)-**1a** (62.6 mg, 0.20 mmol). Purification by column chromatography (98:2 hexanes/EtOAc) afforded (*S*-**2a**) as a yellow solid. Reaction time: 30 min, yield: 54.0 mg (86%) for (PPh₃)AuCl/AgOTf. Reaction time: 30 min, yield: 58.4 mg (93%) for (PPh₃)AuNTf₂. The obtained spectral data matched to those of **2a**. Chiral HPLC Method: Phenomenex Lux 5 μ Cellulose-1 column 250 \times 4.60 mm; Injection volume, 5 μ L; Flow rate, 1.0 mL/min; Elution method, *i*-PrOH/hexane = 1/99 isocratic (0–45 min); UV detection at 254 nm; t_1 = 9.9 min (major isomer), t_2 = 10.9 min (minor isomer): $[\alpha]_D^{20.0}$ -118.9 (c 0.5, MeOH), 87% ee for (PPh₃)AuNTf₂, 83% ee for (PPh₃)AuCl/AgOTf.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra and HPLC chromatograms. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

* E-mail address: ryuj@ewha.ac.kr.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-2015R1A2A2A01004511 and NRF-2014R1A2A1A11050112).

REFERENCES

- (1) For reviews, see: (a) Pinho e Melo, T. M. V. D. *Eur. J. Org. Chem.* **2010**, 3363–3376. (b) Freeman, J. P. *Chem. Rev.* **1983**, 83, 241–261.
- (2) (a) Hubich, A. I.; Zheldakova, T. A.; Chernikhova, T. V.; Koroleva, E. V.; Lakhvich, F. A.; Sholukh, M. V. *Biochem. Biophys. Res. Commun.* **2006**, 341, 357–362. (b) Habeeb, A. G.; Praveen Rao, P. N.; Knaus, E. E. *J. Med. Chem.* **2001**, 44, 2921–2927.
- (3) Carlsen, P. N.; Mann, T. J.; Hoveyda, A. H.; Frontier, A. J. *Angew. Chem. Int. Ed.* **2014**, 53, 9334–9338.
- (4) Aschwanden, P.; Kværnø, L.; Geisser, R. W.; Kleinbeck, F.; Carreira, E. M. *Org. Lett.* **2005**, 7, 5741–5742.
- (5) Sakakura, A.; Hori, M.; Fushimi, M.; Ishihara, K. *J. Am. Chem. Soc.* **2010**, 132, 15550–15552.
- (6) (a) Miyamoto, Y.; Wada, N.; Soeta, T.; Fujinami, S.; Inomata, K.; Ukaji, Y. *Chem. Asian J.* **2013**, 8, 824–831. (b) Gayon, E.; Debleds, O.; Nicouleau, M.; Lamaty, F.; van der Lee, A.; Vrancken, E.; Campagne, J.-M. *J. Org. Chem.* **2010**, 75, 6050–6053. (c) Ishikawa, T.; Kudoh, T.; Yoshida, J.; Yasuhara, A.; Manabe, S.; Saito, S. *Org. Lett.* **2002**, 4, 1907–1910.
- (7) Liguori, A.; Ottana, R.; Romeo, G.; Sindona, G.; Uccella, N. *Tetrahedron* **1988**, 44, 1255–1265.
- (8) (a) Lopes, S. M. M.; Nunes, C. M.; Pinho e Melo, T. M.V.D. *Tetrahedron* **2010**, 66, 6078–6084. (b) Adachi, I.; Harada, K.; Miyazaki, R.; Kano, H. *Chem. Pharm. Bull.* **1974**, 22, 61–69.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (9) (a) Gonzalez-Cruz, D.; Tejedro, D.; de Armas, P.; Garcia-Tellado, F. *Chem. Eur. J.* **2007**, *13*, 4823–4832. (b) Cantagrel, F.; Pinet, S.; Gimbert, Y.; Chavant, P. Y. *Eur. J. Org. Chem.* **2005**, 2694–2701. (c) Busqué, F.; de March, P.; Figueredo, M.; Font, J.; Gallagher, T.; Milán, S. *Tetrahedron: Asymmetry* **2002**, *13*, 437–445. (d) Liguori, A.; Ottana, R.; Romeo, G.; Sindona, G.; Uccella, N. *Tetrahedron* **1988**, *44*, 1247–1253.
- (10) Fabio, M.; Ronzini, L.; Troisi, L. *Tetrahedron* **2008**, *64*, 4979–4984.
- (11) Stoner, E. J.; Roden, B. A.; Chemburkar, S. *Tetrahedron Lett.* **1997**, *38*, 4981–4984.
- (12) Aschwanden, P.; Frantz, D. E.; Carreira, E. M. *Org. Lett.* **2000**, *2*, 2331–2333.
- (13) (a) Debleds, O.; Gayon, E.; Vrancken, E.; Campagne, J.-M. *Beilstein J. Org. Chem.* **2011**, *7*, 866–877. (b) Debleds, O.; Zotto, C. D.; Vrancken, E.; Campagne, J.-M.; Retailleaub, P. *Adv. Synth. Catal.* **2009**, *351*, 1991–1998.
- (14) Wada, N.; Kaneko, K.; Ukaji, Y.; Inomata, K. *Chem. Lett.* **2011**, *40*, 440–442.
- (15) Wei, W.; Kobayashi, M.; Ukaji, Y.; Inomata, K. *Heterocycles* **2009**, *78*, 717–724.
- (16) Wang, D.; Cai, R.; Sharma, S.; Jirak, J.; Thummanapelli, S. K.; Akhmedov, N. G.; Zhang, H.; Liu, X.; Petersen, J. L.; Shi, X. *J. Am. Chem. Soc.* **2012**, *134*, 9012–9019.
- (17) Dondoni, A.; Franco, S.; Junquera, F.; Merchan, F.; Merino, P.; Tejero, T. *Synth. Commun.* **1994**, *24*, 2537–2550.
- (18) Sapeta, K.; Kerr, M. A. *J. Org. Chem.* **2007**, *72*, 8597–8599.
- (19) Wu, K.; Chen, Y.; Lin, Y.; Cao, W.; Zhang, M.; Chen, J.; Lee, A. W. M. *Tetrahedron* **2010**, *66*, 578–582.
- (20) Downey, C. W.; Maxwell, E. N.; Confair, D. N. *Tetrahedron Lett.* **2014**, *55*, 4959–4961.
- (21) Yamashita, Y.; Saito, Y.; Imaizumi, T.; Kobayashi, S. *Chem. Sci.* **2014**, *5*, 3958–3962.
- (22) Pinet, S.; Pandya, S. U.; Chavant, P. Y.; Ayling, A.; Vallee, Y. *Org. Lett.* **2002**, *4*, 1463–1466.
- (23) Wei, W.; Hamamoto, Y.; Ukaji, Y.; Inomata, K. *Tetrahedron: Asymmetry* **2008**, *19*, 476–481.
- (24) Konishi, A.; Wei, W.; Kobayashi, M.; Fujinami, S.; Ukaji, Y.; Inomata, K. *Chem. Lett.* **2007**, *36*, 44–45.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60